Angiotensin II and trials of cardiovascular outcomes11Reprints are not available.

2002/01/01 by Peter Sleight · 8 citations
Medicine · #ACE inhibitor #Angiotensin II #Angiotensin-converting enzyme #Blood Pressure and Hypertension Studies #Blood pressure #Captopril #Cardiology #Enalapril #Heart Failure Treatment and Management #Heart failure #Hormonal Regulation and Hypertension #Hypertensive heart disease #Internal medicine #Medicine #Myocardial infarction #Ramipril #Trandolapril

paper · doi:10.1016/s0002-9149(01)02322-0

openalex publication_date 2002/01/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/29

Cited by

• Genomics, heart failure and sudden cardiac death. [europepmc]
• Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system. [europepmc]
• Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. [europepmc]
• ACE inhibition prevents diastolic Ca2+ overload and loss of myofilament Ca2+ sensitivity after myocardial infarction. [europepmc]
• Treatment of Resistant and Refractory Hypertension. [europepmc]
• Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. [europepmc]
• Interactive Effects of Enalapril Administration and Novel HIIT Wheel-Bed Training in Aged Rats. [europepmc]
• Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-generation Myocardial Repair and Regeneration: Mechanisms and Pre-clinical Evidence. [europepmc]